Trimethoprim nano powder as well as preparation method and application thereof

Trimethoprim nanopowder prepared by low-temperature homogenous grinding and spray drying processes solves the problems of poor water solubility and nano-solution stability, achieves high solubility and bioavailability, and is suitable for drinking water for compound sulfonamide preparations. The mixture is used to improve the biological effects and product stability.

CN118903017APending Publication Date: 2024-11-08SHANDONG DEZHOU SHENNIU ANIMAL HEALTH PROD CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411004795.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The poor water solubility and low dissolution of trimethoprim have limited use in compound sulfonamide preparations, making it difficult to achieve drinking water or intensive waterline administration, and the stability and particle size of the nano solution are uncontrollable, affecting the Industrialized application.

Method used

Using low-temperature homogenized grinding and spray drying technology, trimethoprim was mixed with wetting agent, stabilizer and dispersant to prepare trimethoprim nano powder with D90 not higher than 400 nanometers to improve its solubility in water and Bioavailability and maintain nanoparticle size through spray drying to achieve rapid dispersion and stability.

Benefits of technology

Improve the solubility and dissolution of trimethoprim, achieve rapid dispersion and stability in water, is suitable for dual administration of clinical drinking water and mixing, enhances synergistic effects with sulfonamide drugs, improves bioavailability and products stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903017A_ABST
    Figure CN118903017A_ABST
Patent Text Reader

Abstract

The invention relates to the field of animal preparations, in particular to trimethoprim nano powder and a preparation method and application thereof.The preparation method comprises the following steps that trimethoprim, a wetting agent, a stabilizer, a defoaming agent and a solvent are mixed, and a trimethoprim solution is obtained; carrying out low-temperature homogeneous grinding on the trimethoprim solution to obtain a trimethoprim nano solution, wherein D90 is internally controlled to be not higher than 400 nanometers; and adding a dispersing agent into the trimethoprim nano solution, and carrying out spray drying to obtain the trimethoprim nano powder. And adding sulfonamides raw material medicines and other auxiliary materials into the trimethoprim nano powder to obtain the compound sulfonamides preparation. The trimethoprim nano-powder prepared by the invention can be quickly dissolved in water, is uniformly dispersed, does not settle after being placed, does not aggregate in particle size, is suitable for drinking water administration, has the advantages of high dissolution rate, high bioavailability and simple preparation process, and is convenient for clinical application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of animal preparations, and in particular to a trimethoprim nano powder and a preparation method and application thereof. Background Art

[0002] In drug preparations, except for intravenous administration, regardless of the dosage form and any administration method, the drug must be dissolved in body fluids before it can be absorbed. Drugs with low solubility and slow dissolution often have absorption problems. The solubility and dissolution rate of the drug will directly affect the absorption of the drug in the body and the bioavailability of the drug. Only when the drug is dissolved can it pass through the biological membrane of the gastrointestinal tract, so solubility has always been considered a limiting factor in the absorption process, and the drug crystal form is an important factor affecting solubility. The surface area of ​​drug powder of the same weight increases with the decrease of powder particle diameter. The smaller the drug particle size, the larger the contact area with body fluids. The dissolution rate of the drug is proportional to the surface area of ​​the drug. Therefore, particle size is also an important factor affecting drug dissolution. The greater the solubility and dissolution rate of the drug, the faster the absorption will be. The preparation of nanoparticles has a breakthrough significance.

[0003] Antimicrobial drugs have the advantages of rapid onset and low production cost in the treatment of infectious diseases, making them widely used in clinical practice. However, the limitations of traditional dosage forms and the gradual increase in drug resistance have increased the cost of treatment and reduced the therapeutic effect. For this reason, two or more antimicrobial drugs are often used in combination in clinical practice to expand the antibacterial spectrum, enhance the efficacy, reduce the dosage, reduce or avoid toxic side effects, and reduce or delay the generation of drug-resistant strains. Trimethoprim (TMP) is a synthetic broad-spectrum antimicrobial agent. It is a lipophilic weak base that has antibacterial effects on a variety of Gram-positive and Gram-negative bacteria. It is easy to develop drug resistance when used alone. The mechanism of drug resistance may be that bacteria change metabolic pathways, such as producing more dihydrofolate synthase, or directly using exogenous folic acid. When bacteria develop drug resistance, not only will the efficacy be reduced, but it will also cause the spread of drug-resistant strains, making treatment difficult. Literature reports that trimethoprim, as a broad-spectrum antibacterial agent, can enhance the efficacy of a variety of drugs, such as sulfonamides, macrolides, aminoglycosides, etc., and has a synergistic mechanism for drugs such as tilmicosin and florfenicol. The currently available trimethoprim raw materials are of a powder size of about 80-100 mesh (100 mesh is approximately equal to 150 microns) and are difficult to dissolve in water. Among the preparations included in the 2020 edition of the "Chinese Veterinary Pharmacopoeia", compound sulfachlorpyrifos sodium powder, specification 100g: sulfachlorpyrifos sodium 62.5g + trimethoprim 12.5g; among the preparations included in the 2017 edition of the "Chemical Drugs Volume", compound sulfamethoxazole sodium powder, specification 100g: sulfamethoxazole sodium 10g + trimethoprim 2g. The ratio of sulfonamide raw materials and trimethoprim is 5:1. In compound sulfonamide preparations, sulfonamide sodium salts have good water solubility, and some of them have long-acting functions. Trimethoprim has poor solubility and low solubility, and the duration of synergistic medication is limited. As a result, compound sulfonamide preparations are limited to mixing with feed for administration, and cannot be administered in drinking water or intensive waterline. Clinical applications are limited, and only by improving the solubility and dissolution rate of trimethoprim can it be better used in synergy with sulfonamide drugs.

[0004] In the field of nano-preparation, there are two recognized technical difficulties: first, the stability and repeatability of nano-solutions are poor; second, after the nano-solution is spray-dried, the dry powder is easy to aggregate or coagulate, making the particle size larger and the nano-particle size cannot be restored. Only by properly solving these two technical difficulties can nano-products truly achieve industrialization and achieve the expected goals. Summary of the invention

[0005] In view of this, the present invention aims at the problem of poor water solubility of trimethoprim and discloses a trimethoprim nanopowder with good solubility, high dissolution rate, high bioavailability and simple preparation process, as well as a preparation method and application thereof.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] The first technical purpose of the present invention is to provide a trimethoprim nanopowder, wherein the trimethoprim nanopowder is prepared from the following components, in parts by weight:

[0008] Trimethoprim 30-70 parts, wetting agent 0.1-25 parts, stabilizer 0.1-20 parts, defoamer 0.1-10 parts, dispersant 5-50 parts, solvent 50-400 parts.

[0009] Optionally, the trimethoprim nanopowder is prepared from the following components, in parts by weight:

[0010] 50-70 parts of trimethoprim, 0.2-20 parts of wetting agent, 0.2-15 parts of stabilizer, 0.1-5 parts of defoaming agent, 5-40 parts of dispersant, and 100-300 parts of solvent.

[0011] Further, the wetting agent is one or more of Tween 80, Tween 20, poloxamer, sodium lauryl sulfate, propylene glycol, polyethylene glycol; more preferably, the weight proportion of the wetting agent is 0.4-15.0 parts. The solvent is water or ethanol solution.

[0012] Furthermore, the stabilizer is one or more combinations of sodium carboxymethyl cellulose, xanthan gum, hydroxypropyl methylcellulose, gum arabic, and povidone; more preferably, the weight proportion of the stabilizer is 0.2-10.0 parts.

[0013] Furthermore, the defoaming agent is one or more combinations of dimethyl silicone oil, simethicone, benzyl alcohol, and sucrose ester; more preferably, the weight proportion of the defoaming agent is 0.1-3.0 parts.

[0014] Furthermore, the dispersant is one or more combinations of maltodextrin, lactose, anhydrous glucose, starch, and sucrose; more preferably, the weight proportion of the dispersant is 5.0-35.0 parts.

[0015] The second technical purpose of the present invention is to provide a method for preparing the trimethoprim nanopowder as described above.

[0016] In order to achieve the above object, the present invention adopts the following technical solution:

[0017] A method for preparing trimethoprim nanopowder, the method comprising the following steps:

[0018] (1) mixing trimethoprim, a wetting agent, a stabilizer, a defoaming agent and a solvent to obtain a trimethoprim solution;

[0019] (2) subjecting the trimethoprim solution obtained in step (1) to low-temperature homogenization and grinding to obtain a trimethoprim nano solution;

[0020] (3) adding a dispersant to the trimethoprim nano solution obtained in step (2), filtering, and spray drying to obtain the trimethoprim nano powder.

[0021] It should be noted that the present invention adds a conventional 150 micron trimethoprim to a solvent, a wetting agent, a stabilizer and a defoaming agent to make a trimethoprim suspension, and then grinds the suspension to obtain a suspension with a particle size D90 not higher than 400 nanometers, and then adds a dispersant to the trimethoprim nano liquid, and spray-dries to obtain a trimethoprim nano powder. The nano particle size of the obtained dry powder remains unchanged, and the particle size D90 is still maintained at not higher than 400 nanometers when dissolved in water, and the powder is quickly dispersed and uniformly dispersed in water without aggregation or sedimentation, and is compounded with the required sulfonamide product for application, thereby enhancing the therapeutic effect, realizing the dual administration of clinical drinking water and mixing materials, and increasing solubility and bioavailability.

[0022] Preferably, in step (1), the mass ratio of trimethoprim to solvent is 1:2-20.

[0023] Preferably, the rotation speed of the homogenizing grinding in step (2) is 1500-2500 rpm, and the homogenizing pressure is 0.1-0.3 MPa; the homogenizing grinding is chilled water low-temperature circulation grinding, the homogenizing grinding time is 1-5 hours, and the temperature of the drug solution is controlled between 10-25°C.

[0024] Furthermore, in the step (2), the D50 of trimethoprim in the trimethoprim nano solution is not higher than 200 nanometers, preferably 50-200 nanometers, and the D90 is not higher than 400 nanometers, preferably 200-400 nanometers.

[0025] Preferably, in the step (3), the trimethoprim nano solution is filtered through a 0.22-1 micron filter element and then spray-dried, the spray-drying temperature is 110-130° C., and the internal controlled rapid moisture content of the nano powder after spray drying is 3-8%.

[0026] The third technical purpose of the present invention is to provide the use of the trimethoprim nanopowder as described above in pharmaceutical preparations.

[0027] Specifically, the trimethoprim nanopowder is used in combination with a sulfonamide bulk drug, and then excipients are added (mixed in equal amounts in a stepwise manner) to prepare a compound sulfonamide preparation; wherein,

[0028] The sulfonamide API is one or more of sulfamethoxine, sulfachloropyridazine sodium, sulfamethoxine sodium, sulfamethoxine and different specifications thereof;

[0029] The weight proportion of the sulfonamide raw material is 5.0-65.0 parts of the total weight of the formulation.

[0030] The auxiliary material is one or more combinations of anhydrous glucose, lactose, sucrose, maltose and sorbitol.

[0031] It is worth noting that the present invention belongs to the technical field of antibacterial drug preparations for animals, and the involved trimethoprim nanopowder is used for compatibility with sulfonamide drugs. Trimethoprim is a special antibacterial synergist, and can produce synergistic effects when combined with sulfonamide drugs. Sulfonamide sodium salt is easily soluble in water and dissolves quickly, while the solubility of trimethoprim raw materials in water is very low. There are documents reporting that the solubility of trimethoprim in water for 5 minutes is only 26.5%, and the solubility in 2 hours is only 54.1%. It is necessary to adopt a suitable preparation method to improve the solubility of trimethoprim, thereby improving bioavailability. The present invention converts ordinary trimethoprim raw materials into trimethoprim nanopowder through nano-preparation technology to increase the solubility of trimethoprim raw materials, improve dissolution and bioavailability, realize dual administration of drinking water and mixing feed, and is suitable for large-scale breeding mode.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] (1) The preparation process of the trimethoprim nanopowder disclosed in the present invention is simple, has good reproducibility, strong operability, and is green, safe and pollution-free.

[0034] (2) The present invention processes trimethoprim, which has low solubility and poor water solubility, into a nano powder through a special process, and finally obtains a nano powder with high solubility and strong water solubility. After being dissolved in water, the nano particle size remains unchanged before drying, which is convenient for clinical medication.

[0035] (3) The trimethoprim nanopowder prepared by the present invention has good product stability, high bioavailability, and no change in particle size after long-term storage.

[0036] (4) The trimethoprim nanopowder prepared by the present invention is obtained by low temperature homogenization of trimethoprim with a conventional particle size of 150 microns into a powder with a particle size D90 not higher than 400 nanometers, so that the product dissolves quickly without blocking the water line, and can be administered by mixing with feed and drinking water. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0038] Figure 1 It is a particle size diagram of compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention.

[0039] Figure 2 It is a favorable granularity map of the control group.

[0040] Figure 3 This is a comparison chart of the solubility of compound sulfamethoxazole sodium powder in water.

[0041] Figure 4 This is a comparison chart of the blood drug concentration of compound sulfamethoxazole sodium powder. DETAILED DESCRIPTION

[0042] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] The word "embodiment" used here as an "exemplary" does not necessarily mean that any embodiment described is superior to or better than other embodiments. Unless otherwise specified, the performance index tests in the embodiments of this application are performed using conventional test methods in the art. It should be understood that the terms described in this application are only used to describe specific implementation methods and are not used to limit the content disclosed in this application.

[0044] Unless otherwise specified, the technical and scientific terms used in this document have the same meanings as commonly understood by ordinary technicians in the technical field to which this application belongs; other experimental methods and technical means not specifically specified in this application refer to experimental methods and technical means commonly used by ordinary technicians in this field.

[0045] In order to better illustrate the content of the present application, numerous specific details are provided in the specific examples below. It should be understood by those skilled in the art that the present application can also be implemented without certain specific details. In the embodiments, some methods, means, instruments, equipment, etc. well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present application.

[0046] Under the premise of no conflict, the technical features disclosed in the embodiments of the present application can be combined arbitrarily, and the resulting technical solutions belong to the contents disclosed in the embodiments of the present application.

[0047] The invention discloses a preparation method and application of trimethoprim nano powder.

[0048] In order to better understand the present invention, the present invention is further specifically described below through the following examples, but it should not be understood as a limitation of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above invention content are also considered to fall within the protection scope of the present invention.

[0049] Example 1

[0050] The preparation of trimethoprim nanopowder is specifically as follows:

[0051] 20kg of trimethoprim, 0.2kg of sodium lauryl sulfate, 2kg of hypromellose, 0.5kg of simethicone emulsion, 10kg of maltodextrin, and appropriate amount of purified water.

[0052] The preparation of trimethoprim nano powder is divided into three parts: preparation of trimethoprim solution, homogenization of trimethoprim nano solution, and spray drying of trimethoprim nano solution to prepare trimethoprim nano powder.

[0053] (I) Preparation of trimethoprim solution:

[0054] Weigh 15 kg of purified water, add 0.2 kg of sodium dodecyl sulfate, stir to dissolve and clarify, add 20 kg of trimethoprim to make solution 1.

[0055] Add 2 kg of Hydroxypropyl Methylcellulose to 10 kg of purified water and stir until dissolved to obtain Solution 2.

[0056] Add 5 kg of purified water to 0.5 kg of simethicone emulsion, stir and disperse evenly to obtain solution 3.

[0057] Solution 2 was added to solution 1, and after stirring evenly, solution 3 was added, and the mixture was stirred and dispersed for 30 minutes to obtain solution 4.

[0058] (II) Homogenization of trimethoprim nano solution:

[0059] The trimethoprim solution 4 was ground and homogenized using a special homogenizing equipment, with a homogenizing speed of 1800 rpm, a homogenizing pressure of 0.2 MPa, a cooling water temperature of 7° C., a liquid temperature controlled between 15 and 20° C., and low-temperature circulation grinding for 4 hours to obtain a solution 5.

[0060] The particle size was detected online during the homogenizing and grinding process, and the detected particle size D90 was no higher than 400 nanometers, thereby obtaining a trimethoprim nano solution 6.

[0061] (III) Spray drying of trimethoprim nano solution:

[0062] Weigh 50 kg of purified water, add 10 kg of maltodextrin, stir to dissolve and clarify, and add to solution 6 to obtain solution 7.

[0063] The air inlet temperature was set to 120° C. and the atomization pressure was set to 0.2 MPa. The nano solution 7 was filtered online through a 0.22 μm filter element and spray-dried to obtain trimethoprim nano powder.

[0064] The theoretical content of trimethoprim nanopowder is about 61%, and the detected particle size D90 is not higher than 400 nanometers.

[0065] (IV) Preparation of trimethoprim nanoparticles (compound sulfamethoxazole sodium powder):

[0066] The trimethoprim nanopowder prepared in Example 1 was prepared into a preparation of compound sulfamethoxine sodium powder, with a specification of 100g: sulfamethoxine sodium 10g + trimethoprim 2g, and the trimethoprim in the compound sulfamethoxine sodium preparation was nanometer-grade. The method is as follows:

[0067] Weigh 10kg of sulfamethoxazole sodium and 3.3kg of trimethoprim nanopowder, add equal amounts and mix evenly, add lactose to 100kg, and package after passing the test.

[0068] Example 2

[0069] The preparation of trimethoprim nanopowder is specifically as follows:

[0070] Trimethoprim 30kg, Tween 80 5kg, sodium carboxymethyl cellulose 1kg, sucrose ester 0.5kg, lactose 10kg, and appropriate amount of purified water.

[0071] The preparation of trimethoprim nano powder is divided into three parts: preparation of trimethoprim solution, homogenization of trimethoprim nano solution, and spray drying of trimethoprim nano solution to prepare trimethoprim nano powder.

[0072] (I) Preparation of trimethoprim solution:

[0073] Weigh 60 kg of purified water, add 5 kg of Tween 80, stir to dissolve and clarify, and add 30 kg of trimethoprim to obtain Solution 1.

[0074] Add 15 kg of purified water to 1 kg of sodium carboxymethyl cellulose and stir until dissolved to obtain solution 2.

[0075] Add 0.5 kg of sucrose ester to 15 kg of purified water, heat to 70°C, stir and disperse evenly to obtain Solution 3.

[0076] Solution 2 was added to solution 1, and after stirring evenly, solution 3 was added, and the mixture was stirred and dispersed for 30 minutes to obtain solution 4.

[0077] (II) Homogenization of trimethoprim nano solution:

[0078] The trimethoprim solution 4 was ground and homogenized using a special homogenizing equipment, with a homogenizing speed of 2200 rpm, a homogenizing pressure of 0.25 MPa, a cooling water temperature of 10°C, a liquid temperature controlled between 15-25°C, and low-temperature circulation grinding for 3 hours to obtain a solution 5.

[0079] The particle size was detected online during the homogenizing and grinding process, and the detected particle size D90 was no higher than 400 nanometers, thereby obtaining a trimethoprim nano solution 6.

[0080] (III) Spray drying of trimethoprim nano solution:

[0081] Weigh 60 kg of purified water, add 10 kg of lactose, stir until dissolved and clarified, and add to solution 6 to obtain solution 7.

[0082] The air inlet temperature was set to 115° C. and the atomization pressure was set to 0.2 MPa. The nano solution 7 was filtered online through a 0.45 μm filter element and spray-dried to obtain trimethoprim nano powder.

[0083] The theoretical content of trimethoprim nanopowder is about 64.5%, and the detected particle size D90 is not higher than 400 nanometers.

[0084] (IV) Preparation of trimethoprim nanoparticles (compound sulfamethoxazole sodium soluble powder):

[0085] The trimethoprim nanopowder prepared in Example 2 was prepared into compound sulfamethoxine sodium soluble powder, with a specification of 100g: sulfamethoxine sodium 20g + trimethoprim 4g, and the trimethoprim in the compound sulfamethoxine sodium soluble powder preparation was nanometer-grade. The method is as follows:

[0086] Weigh 20kg of sulfamethoxazole sodium and 6.2kg of trimethoprim nanopowder, add equal amounts and mix evenly, add lactose to 100kg, and package after passing the test.

[0087] Example 3

[0088] The preparation of trimethoprim nanopowder is specifically as follows:

[0089] 25kg of trimethoprim, 5kg of poloxamer, 0.1kg of xanthan gum, 2kg of benzyl alcohol, 8kg of soluble starch, and appropriate amount of purified water.

[0090] The preparation of trimethoprim nano powder is divided into three parts: preparation of trimethoprim solution, homogenization of trimethoprim nano solution, and spray drying of trimethoprim nano solution to prepare trimethoprim nano powder.

[0091] (I) Preparation of trimethoprim solution:

[0092] Weigh 50 kg of purified water, add 5 kg of poloxamer, stir to dissolve and clarify, add 25 kg of trimethoprim to obtain solution 1.

[0093] Add 0.1 kg of xanthan gum to 10 kg of purified water and stir until dissolved to obtain solution 2.

[0094] Add 2 kg of benzyl alcohol to 5 kg of purified water and stir to disperse evenly to obtain solution 3.

[0095] Solution 2 was added to solution 1, and after stirring evenly, solution 3 was added, and the mixture was stirred and dispersed for 30 minutes to obtain solution 4.

[0096] (II) Homogenization of trimethoprim nano solution:

[0097] The trimethoprim solution 4 was ground and homogenized using a special homogenizing equipment, with a homogenizing speed of 2000 rpm, a homogenizing pressure of 0.2 MPa, a cooling water temperature of 7° C., a liquid temperature controlled between 10 and 20° C., and low-temperature circulation grinding for 4 hours to obtain a solution 5.

[0098] The particle size was detected online during the homogenizing and grinding process, and the detected particle size D90 was no higher than 400 nanometers, thereby obtaining a trimethoprim nano solution 6.

[0099] (III) Spray drying of trimethoprim nano solution:

[0100] Weigh 50 kg of purified water, add 8 kg of soluble starch, stir until dissolved and clarified, and add to solution 6 to obtain solution 7.

[0101] The air inlet temperature was set to 120° C. and the atomization pressure was set to 0.2 MPa. The nano solution 7 was filtered online through a 0.6 μm filter element and spray-dried to obtain trimethoprim nano powder.

[0102] Trimethoprim nano powder, theoretical content 62%. Detection particle size D90 is not higher than 400 nanometers.

[0103] (IV) Preparation of trimethoprim nanoparticle preparation (compound sulfachloropyridazine sodium powder):

[0104] The nano trimethoprim nano powder prepared in Example 3 was prepared into compound sulfachloropyridazine sodium powder, with a specification of 100g: sulfachloropyridazine sodium 62.5g + trimethoprim 12.5g, and the trimethoprim in the compound sulfachloropyridazine sodium powder preparation was nanometer-grade. The method is as follows:

[0105] Weigh 62.5 kg of sulfasulfachloropyridazine sodium and 20.16 kg of trimethoprim nanopowder, add equal amounts gradually and mix evenly, add anhydrous glucose to 100 kg, and package after passing the test.

[0106] The compound sulfamethoxazole sodium preparation prepared in Example 1 of the present invention was compared with the control sample imported product Lihao (Li Lan Animal Health Co., Ltd.) to conduct various tests of trimethoprim, including particle size test, solubility test, dissolution test, blood drug concentration test and stability test, as follows:

[0107] 1. Particle size comparison test:

[0108] Test method: The compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention and the control group Lihao (Li Lan Animal Health Co., Ltd.) were prepared into a 10% solution (sulfamethoxazole sodium), the stirring speed was 300r / min, the stirring time was 60 seconds, and the particle size and particle size distribution determination method of the Chinese Veterinary Pharmacopoeia was used for detection. The results are shown in Table 1 below. Figure 1 and Figure 2 :

[0109] Table 1 Comparative test results of the particle size of compound sulfamethoxazole sodium powder

[0110]

[0111] Result analysis: The particle size D90 of compound sulfamethoxazole sodium powder solution is 306 nanometers, the particle size D90 of the control group is 37110 nanometers, and the particle size of the solution of the product of the present invention is significantly better than that of the control group.

[0112] 2. Solubility comparison test:

[0113] Test method: The compound sulfamethoxine sodium powder prepared in Example 1 of the present invention and the control group Lihao (Li Lan Animal Health Co., Ltd.) were both prepared into a 20% solution (sulfamethoxine sodium), the stirring speed was 300r / min, the stirring time was 60 seconds, the dissolution phenomenon was observed after the stirring was stopped, and the dissolution phenomenon was observed after standing for 8 hours. The results are shown in Table 2 below.

[0114] Table 2 Solubility comparison test results of compound sulfamethoxazole sodium powder

[0115]

[0116]

[0117] Result analysis: The compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention is still uniformly dispersed in a high-concentration 20% solution state after being placed for 8 hours without precipitation, and its solubility is significantly better than that of the control group.

[0118] 3. Dissolution comparison test:

[0119] Test method: According to the method for determining the content of trimethoprim and the method for determining the solubility of trimethoprim in the 2020 edition of the Chinese Veterinary Pharmacopoeia, the compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention and the control group were weighed, and the solubility in water was determined in the same manner. The solubility of trimethoprim raw materials was determined at 5 minutes, 20 minutes, 40 minutes, 60 minutes, 80 minutes, 100 minutes and 120 minutes, respectively. The results are shown in Table 1. Figure 3 .

[0120] The results analysis, from Figure 3The solubility of the compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention in water for 5 minutes is as high as 75.6%, which is significantly better than that of the control group.

[0121] 4. Bioavailability comparison test:

[0122] Experimental method: The design was divided into 2 groups, namely the favorable (imported control) group and Example 1 compound sulfamethoxazole sodium powder. The pigs were randomly divided into 2 groups, fasted for 12 hours, and administered orally by gavage. Blood was collected at 0h, 0.08h, 0.25h, 0.5h, 0.75h, 1h, 1.25h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h and 48h, respectively. The blood samples were processed and the blood concentration of trimethoprim nanopowder was determined by HPLC. The results are shown in Table 1. Figure 4 .

[0123] from Figure 4 In the test, the blood concentration of trimethoprim nanopowder in each period of the compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention was significantly better than that in the control group. At 0.75 hours, the blood concentration of trimethoprim nanopowder was 1.9ug / mL, and the blood concentration of the positive group was 1.05ug / mL. By comparing the data, the trimethoprim drug was rapidly dissolved, released and reached the peak concentration, reflecting the rapid release, high solubility, high release and high bioavailability of trimethoprim nanopowder.

[0124] 5. Stability test:

[0125] Test method: The compound sulfamethoxazole sodium powder prepared in Example 1 was subjected to an accelerated test according to the Chinese Pharmacopoeia standard, with the temperature set at 40°C ± 2°C and the relative humidity at 75% ± 5%. The properties, identification, loss on drying, content of trimethoprim raw material and others were evaluated in October, January, February, March and June. The results are shown in Table 3 below.

[0126] Table 3 Compound sulfamethoxazole sodium powder sample test results

[0127]

[0128] The results show that the thermal accelerated stability of the compound sulfamethoxazole sodium powder prepared in Example 1 of the present invention is tested for 6 months, and all indicators meet the requirements, indicating that the quality of this product is stable and controllable.

[0129] In summary, the trimethoprim nano powder disclosed in the present invention has a D90 not higher than 400 nanometers, excellent water solubility, uniform dispersion in water, no sedimentation after being placed for 8 hours, and a dissolution rate of 75.6% in 5 minutes in water, and a simple preparation method, a safe and environmentally friendly production process, and a good stability of the prepared compound sulfamethoxazole sodium powder, which is suitable for large-scale industrial production. Compared with similar products, it has a finer particle size, extremely high solubility and high dissolution, is convenient for various clinically required administration methods, and compared with the "good" of imported products, the blood drug concentration in each time period is better than the good, and the characteristics of long-term effect and stable release in vivo can be achieved. Therefore, the implementation and promotion of the scheme of the present invention will surely promote the transformation of nano preparations, and have good clinical applications and market prospects.

[0130] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A trimethoprim nanopowder, characterized in that: The trimethoprim nanopowder is prepared from the following components, in parts by weight: Trimethoprim 30-70 parts, wetting agent 0.1-25 parts, stabilizer 0.1-20 parts, defoamer 0.1-10 parts, dispersant 5-50 parts, solvent 50-400 parts.

2. The trimethoprim nanopowder according to claim 1, characterized in that The trimethoprim nanopowder is prepared from the following components, in parts by weight: 50-70 parts of trimethoprim, 0.2-20 parts of wetting agent, 0.2-15 parts of stabilizer, 0.1-5 parts of defoaming agent, 5-40 parts of dispersant, and 100-300 parts of solvent.

3. The trimethoprim nanopowder according to claim 1 or 2, characterized in that: The wetting agent is one or more combinations of Tween 80, Tween 20, poloxamer, sodium lauryl sulfate, propylene glycol, and polyethylene glycol; and the solvent is water or ethanol solution.

4. The trimethoprim nanopowder according to claim 1 or 2, characterized in that: The stabilizer is one or more combinations of sodium carboxymethyl cellulose, xanthan gum, hydroxypropyl methylcellulose, gum arabic, and povidone; the defoaming agent is one or more combinations of dimethyl silicone oil, simethicone, benzyl alcohol, and sucrose ester; the dispersant is one or more combinations of maltodextrin, lactose, anhydrous glucose, starch, and sucrose.

5. A method for preparing trimethoprim nanopowder according to any one of claims 1 to 4, characterized in that: The method specifically comprises the following steps: (1) mixing trimethoprim, a wetting agent, a stabilizer, a defoaming agent and a solvent to obtain a trimethoprim solution; (2) subjecting the trimethoprim solution obtained in step (1) to low-temperature homogenization and grinding to obtain a trimethoprim nano solution; (3) adding a dispersant to the trimethoprim nano solution obtained in step (2), filtering, and spray drying to obtain the trimethoprim nano powder.

6. The method for preparing trimethoprim nanopowder according to claim 5, characterized in that: In the step (1), the mass ratio of trimethoprim to solvent is 1:2-20.

7. The method for preparing trimethoprim nanopowder according to claim 5, characterized in that: The rotation speed of the homogenizing grinding in the step (2) is 1500-2500 rpm, and the homogenizing pressure is 0.1-0.3 MPa; the homogenizing grinding is low-temperature circulating grinding with chilled water, the homogenizing grinding time is 1-5 hours, and the temperature of the drug solution is controlled between 10-25° C.; the D50 of trimethoprim in the trimethoprim nano solution is not higher than 200 nanometers, and the D90 is not higher than 400 nanometers.

8. The method for preparing trimethoprim nanopowder according to claim 5, characterized in that: In the step (3), the trimethoprim nano solution is filtered through a 0.22-1 micron filter element and then spray dried. The spray drying temperature is 110-130° C., and the internal controlled rapid moisture content of the nano powder after spray drying is 3-8%.

9. Use of the trimethoprim nanopowder according to any one of claims 1 to 4 or the trimethoprim nanopowder prepared by the method according to claim 5 in a pharmaceutical preparation.

10. The use according to claim 9, characterized in that: The trimethoprim nanopowder is used in combination with a sulfonamide bulk drug, and then an auxiliary material is added to prepare a compound sulfonamide preparation; wherein, The sulfonamide API is one or more combinations of sulfamethoxine, sulfachloropyridazine sodium, sulfamethoxine sodium, and sulfa-paramethoxine, and the sulfonamide API has different specifications; The auxiliary material is one or more combinations of anhydrous glucose, lactose, sucrose, maltose and sorbitol.